Clinical Trial Update: Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating cilengitide for recurrent and/or metastatic squamous cell carcinoma of the head and neck has completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• cilengitide (cilengitide)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Squamous Cell Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-04-30